Repmono: a lightweight self-supervised monocular depth estimation architecture for high-speed inference

Abstract Self-supervised monocular depth estimation has always attracted attention because it does not require ground truth data. Designing a lightweight architecture capable of fast inference is crucial for deployment on mobile devices. The current network effectively integrates Convolutional Neural Networks (CNN) with Transformers, achieving significant improvements in accuracy. However, this advantage comes at the cost of an increase in model size and a significant reduction in inference speed. In this study, we propose a network named Repmono, which includes LCKT module with a large convolutional kernel and RepTM module based on the structural reparameterisation technique. With the combination of these two modules, our network achieves both local and global feature extraction with a smaller number of parameters and significantly enhances inference speed. Our network, with 2.31MB parameters, shows significant accuracy improvements over Monodepth2 in experiments on the KITTI dataset. With uniform input dimensions, our network’s inference speed is 53.7% faster than R-MSFM6, 60.1% faster than Monodepth2, and 81.1% faster than MonoVIT-small. Our code is available at https://github.com/txc320382/Repmono

Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma

Abstract Backgroud Endoscopic surgery can be used as the main treatment for advanced recurrent nasopharyngeal carcinoma (rNPC). However, there is a huge clinical controversy about the need for consolidated immunotherapy after surgery. Methods We performed a retrospective propensity score-matched analysis (1:2) of patients with locally advanced rNPC who underwent endoscopic nasopharyngectomy (ENPG) combined with anti-programmed cell death protein-1 (PD-1) monotherapy or ENPG alone. The survival rate was analyzed by Kaplan–Meier method. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), objective response rate (ORR) and disease control rate (DCR). Potential surgical-related complications and immune-related adverse events (AEs) were also assessed. Results We recruited 10 patients receiving ENPG plus anti-PD-1 monotherapy and 20 receiving ENPG alone. During the mean follow-up of 23.8 months, a significant improvement in the 2-year PFS was detected in the consolidation immunotherapy group compared to the ENPG alone group (80.0% vs. 40.0%; HR = 0.258; 95% CI: 0.09–0.72; p = 0.04), while the 2-year OS in the consolidation immunotherapy group was not significantly longer than that in the ENPG alone group (90.0% vs. 75.0%; HR = 0.482; 95% CI: 0.08–3.00; p = 0.50). The incidence of surgical-related complications in the consolidation immunotherapy group and ENPG alone group was 70.0 and 60.0%, respectively. Immune-related AEs were similar between the toripalimab arm (75.0%) and the camrelizumab arm (66.7%). Surgical-related complications depend on symptomatic treatments. Immune-related AEs were mild and tolerable. Conclusions Consolidation immunotherapy regimen for patients with advanced rNPC after ENPG compared to ENPG alone provides a superior PFS rate with a manageable safety profile